Neuroprotective and consequent neurorehabilitative clinical outcomes, in 
patients treated with the pleiotropic drug cerebrolysin by Onose, G et al.
Journal of Medicine and Life Vol. 2, No.4, October-December 2009, pp.350-360  
  © 2009, Carol Davila University Foundation 
 
 
Neuroprotective and consequent neurorehabilitative clinical 
outcomes, in patients treated with the pleiotropic  
drug cerebrolysin 
 
G. Onose*’ **, D.F. Mureşanu***, A.V. Ciurea**’ ****, C. Daia Chendreanu*’ **, A. S. Mihaescu*, 
    D.C. Mardare*, I. Andone*, A. Spânu*, C. Popescu*, A. Dumitrescu*, 
    M. Popescu*****, V. Grigorean*’ **, B. Ungur*, F. Marinescu*, 
  I. Colibăşeanu*, L. Onose******, M. Haras*’ **, A. Sandu*, T. Spircu** 
 *‘Bagdasar-Arseni’ Teaching Emergency Hospital, Bucharest, Romania 
**”Carol Davila” (State) University of Medicine and Pharmacy, Bucharest, Romania 
***The Neurological Clinic of ‘Iuliu Hatieganu’ (State) University of Medicine and Pharmacy, Cluj-Napoca, Romania 
****The Ist Clinic Division of Neurosurgery, ‘Bagdasar-Arseni’ Teaching Emergency Hospital, Bucharest, Romania  
*****The Neurosurgery Division of the County Hospital, Pitesti, Romania 
******The Medical Service of Metrorex, Bucharest, Romania 
 
Correspondence to: G. Onose, M.D PhD 
‘Bagdasar-Arseni’ Teaching Emergency Hospital  
10-12 Berceni Street, District 4, Bucharest, Romania 
 
Received: September 1st, 2009 – Accepted: September 25th, 2009 
 
 
Abstract 
Background: Discovery of neurotrophic factors - emblematic: the nerve growth factor (NGF) - resulted in better 
approaching central nervous system (CNS) lesions. Recently, another crucial property has been unveiled: their rather 
unique pleiotropic effect. Cerebrolysin is a peptide mixture that penetrates the blood-brain barrier in significant amounts 
and mimics the effects of NGF. 
Methods: Comparative analysis: Cerebrolysin treated (10 ml x 2/ day, i.v. x 3 weeks) vs. non-treated, in patients (all 
received aside, a rather equivalent complementary, pharmacological and physical, therapy). Two lots of patients, 
admitted in our Physical & Rehabilitation (neural-muscular) Medical - PR(n-m)M - Clinic Division, during 2007-2009: 69 
treated with Cerebrolysin (22 F, 47 M; Average: 59.333; Mean of age: 61.0 Years old; Standard deviation 16.583) and 70 
controls (41 F, 29 M; A: 70.014; M.o.a.: 70.5 Y.o.; S.d.: 6.270) were studied. The total number of assessed items was 
13: most contributive in relation with the score of Functional Independence Measure at discharge (d FIM), were: 
admission (a FIM), number of physical therapy days (PT), number of hospitalization days (H), age (A) and - relatively - 
days until the first knee functional extension (KE). Concomitantly, the main/ key, focused on neuro-motor rehabilitative 
outcomes, functional/analytical parameters, have been assessed regarding the speed in achieving their functional 
recovery. 
Results: Concerning d FIM, there have not been objectified significant differences between the two lots (p=0.2453) 
but regarding key, focused on neuro-motor rehabilitative outcomes, functional/analytical parameters: KE (p=0.0007) and 
days until the first time recovery of the ability to walk between parallel bars (WPB - p=0.0000) – highly significant 
differences in favor of Cerebrolysin lot resulted. 
Conclusion: Cerebrolysin administration, as neurorehabilitative outcomes, proved to hasten, statistically significant, 
especially the recovery of some critical, for standing and walking, parameters. Thus encouraged, we have now initiated a 
comprehensive national, 5 year retrospective, multi-centre - based on unitary data acquisition frame and mathematical 
apparatus – study, to evaluate the results of the treatment with Cerebrolysin in traumatic brain injuries (TBI). 
Introduction 
In 1986, Rita Levi-Moncalcini (from The Cellular 
Biology Institute, Rome, Italy) and Stanley Cohen (from 
the Vanderbilt University School of Medicine, Nashville, 
USA) received the Nobel Prize for discovering 
neurotrophic factors: the nerve growth factor - NGF - 
respectively, the epidermal growth factor - EGF. 
Since then, many other neurotrophic factors have 
been identified: they are polypeptides, naturally 
synthesized by all types of cells within the CNS and also 
by other tissues. Their activity is essential for the NS 
development (they stimulate cell proliferation and Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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differentiation, respectively axonal and dendritic growth), 
for the neural cells’ natural survival in the absence of 
injury/resistance to noxious factors and for their 
phenotype retaining, during lifetime.     
Neurotrophic factors stimulate neural plasticity and 
synaptic activity, and therefore are important for both: 
learning processes and for the NS’s impressive ability to 
spontaneously reorganize and thus, clinical 
adapt/(limited) self-recover, after different injuries. 
The discovery of neurotrophic factors - emblematic: 
NGF - resulted in better approaching CNS lesions. 
Recently, another crucial property has been unveiled: 
their rather unique pleiotropic effect [1] – i.e. a combined, 
complex neuroprotection and neurotrophicity (including 
neural plasticity) stimulation. 
CNS injuries are divided into two main categories: 
primary - which occur (mainly) at the moment of a trauma 
- and secondary ones, that develop after the initial injury, 
as a consequence of a complex and rather specific to 
CNS, patho-physiological events’ cascade; they produce 
effects that may continue for a long time. The secondary 
injury process (synthetically including: excessive 
synthesis of nitric oxide and oxidative stress, microglia 
activation, local inflammation, disturbance of 
microcirculation, blood-brain barrier dysfunction and the 
most recently acknowledged ”delayed mechanisms of 
cell death”[2,3,4,5] ) leads in vicious circles, to disastrous 
consequences: 
- neuronal necrosis; 
- neuronal apoptosis; 
- scar and/or cyst/ hygroma formation - with further - 
pathogenic effects on CNS tissue; 
- demyelination; 
- disruption of morpho-functional nerve pathways 
(disconnection) and/or functional uncoupling, such 
as diaschisis. 
Thus, minimizing the secondary damage “cascade” 
could result in maximizing post-injury favorable 
evolution/recovery, including more rapid and consistent 
neuro-rehabilitative outcomes.  
Therefore, the CNS intimate mechanisms of the 
secondary injuries are, at present, main targets for 
modern, including pleiotropic, complex therapies. 
CNS main pathways for the secondary damage 
(occurring in the affected area and in its neighborhood): 
1. Breakdown of the primary traumatized area’s 
cells.  
2. Breakdown of the myelin sheath’s structure. 
3. Release, from inside the disrupted CNS cells - 
mitochondria are important sources - of reactive oxygen 
species (ROS). 
4. Microglia activation including pro-inflammatory, 
with subsequent delivery of cytokines from these injured 
structures and of wall components, as well (together - in 
vicious circle) with supplementary amounts of ROS - as a 
result of ROS peroxidation lesions of membranes’ 
phospholipids (under excessive, post tissue injury - 
including neural - metabolic, mitochondrial/ cell 
hyperactivity). 
5. Oxidative stress - the (hyper) local metabolic 
generation of ROS and physiological antioxidants’ 
depletion, with subsequent alteration of some gene 
expression functions (especially for factors/ 
transcriptional mechanisms type: NF-kB, PPAR, AP-1) 
and thus priming, including synthesis sequences, that 
stimulates production of pro-inflammatory cytokines - 
especially interleukins IL-1, IL-6 and tumor necrosis 
factor (TNF)  α – respectively, with concomitantly 
reduction of related molecules synthesis (but with anti-
mediator role - for example: IL-2). 
6. Immune imbalance/inflammation. 
7. Disorder of local microcirculation and integrity of 
the blood-brain barrier (with consecutive regional 
ischemia and edema). 
8. Electrolyte disorders, including massive edema - 
CNS tissue swelling - induced by suddenly installed 
osmolysis (often one of the direct effects of primary 
injury, too) subsequent to the affected cells which die 
passively – thus, violent osmolysis is also, in such 
circumstances, a main necrosis mechanism: in necrosis 
it is the cellular edema which leads to osmolysis, with the 
cell passively dying off. 
9. Increase of the nervous tissue metabolism, 
including oxygen consumption, thus resulting, in the 
vicious circle, of its sensitivity to hypoxia and - once more 
– ischemia. 
10. Large amounts of tiny molecules - Transient 
Receptor Potential Member (TRPM) 7 - invade the 
normal surrounding neurons’ membrane surfaces and 
very probably, mainly through adenil-cyclase, 
dramatically enhance their oxidative metabolic activity, 
resulting in more ROS that propagates the damages to 
an extensive cell (both) apoptosis and necrosis process, 
in the unaffected neighborhood, too. 
11. Resulting in a relative excess of exciting 
neurotransmitters and massive influx of intracellular 
(toxic/metabolic destructive) calcium ions (see further). 
12. Sequential activation of key-role genes, including 
(most dangerous for a non-regenerating tissue, like CNS 
– as neurons lack centrosomes) those for  apoptosis - 
triggering the "mechanisms of delayed cell death": 
programmed cell suicide and apoptosis-like processes - 
most recently emphasized, having a longer display and 
being produced at an intimate level, mainly through 
metabolic disturbance of aggregated proteins involved in 
the deep mechanisms of cellular  reproductive cycles/ 
vitality-survival [1,6,7].  
Briefly, it is worth to synthetically emphasize some of 
the main beneficial actions but it also limits/side effects - 
related to the pleiotropic effect subject matter - of one of 
the most studied and controversially used - including in 
CNS acute lesions - drug, with strong anti-inflammatory 
properties: metilprednisolone (MP). The most important 
action of MP in the acute stage of injury is to inhibit the Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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lipid peroxidation induced by ROS, thus limiting the 
secondary damage. The antioxidant effects of MP are 
not mediated via glucocorticoid receptors: other steroidal 
anti-inflammatory drugs (SAIDs) do not possess similar 
antioxidant activity [8]. 
MP interferes with other neural pathological 
pathways, too: 
•  decreases the arachidonic acid release; 
•  lowers the cellular inflow of calcium ions and 
subsequently, the apoptosis processes; 
•  decreases anaerobic metabolism and prevents 
(toxic) lactate/acidosis accumulation; 
•  minimizes neurofilaments degeneration; 
•  reduces post-traumatic nevrax  edema and its 
compressive consequences; 
•  helps maintaining the neuronal membrane 
potential and the synaptic transmission. 
Adverse actions: in the recent years, the use of high-
dose MP has become controversial, mostly based on the 
risk of serious side effects versus a modest neurological 
benefit. The steroid side effects are prominent when the 
treatment is extended beyond 24 hours: pneumonias, 
septic shocks, wound infection, delayed wound healing, 
pressure sores, hyperglycemia, deep-vein thrombosis, 
gastro-intestinal bleedings [9-12]. 
Other limitations to high-dose MP therapy: the  
 
neuroprotective properties of MP have a sharp U-shaped 
dose-response curve, that requires careful dose 
calculation; initiation of treatment beyond the 8-hour 
opportunity window can exacerbate damages: inhibition 
of axonal budding and synaptogenesis. Considering the 
long term neurological outcome, the potential of the 
steroid to attenuate post-injury neural plasticity is 
probably the most serious concern regarding the 
administration of high doses of MP. 
13. Higher concentrations of calcium ions, extruded 
on the exterior of the nerve cells' break, flood the interior 
of these   (and also other, non-affected) neurons [13]. In 
the attempt of regaining the pressure’s balance of the 
ionic concentrations, calcium sets off a series of self-
destructive cellular events, among which very important 
is: its interference, at mitochondrial level, with the 
electron transport/acceptor chain, thus resulting in a 
greater amount of ROS (Fig. 1). 
14. Injury releases amounts of different neuro-
transmitters higher than usual: catecholamines, 
endorphins, serotonin and (most “dangerous”, especially 
in the early post-injury stages) glutamate, the main 
excitatory normal neuro-transmitter; in large, abnormal, 
amounts without enough valid neurons to respond to, 
glutamate  expresses  its  toxicity  by overloading intact 
remaining neuronal  circuits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Glutamate increases Ca2+ cellular influx, activating neuronal nitric oxide-synthetase (nNOS); this enzyme, in the presence 
of Ca2+ absorbed at mitochondria level, converts nitric oxide (NO) in peroxinitrite (ONOO-): one of the most toxic ORS; Ca2+ and 
ONOO-, apparently paradoxical, blocks the mitochondrial breathing (in terms of oxidative metabolic hyperactivity, which is 
induced by Ca2+); concomitantly/ consequently, at the respiratory chain level, increases the production of ROS. It results: 
energetical mitochondrial collapse, damaging (predominantly by peroxidation) the membranar lipids - with propensive 
permeabilisation getting out from mitochondrias and translocating to the nucleus of AIF - and DNA by ROS (mainly ONOO-) and 
respectively, secondary hiperactivation of poly-ADP-ribozo-polymerase (PARP) -1 enzyme; the latter convey the signals of cell 
suicide by engramated, preformated way on nuclear level, through chemical-energetical revolving plate’s depletion, represented 
by nicotine-amide-dinucleotide (NAD)+/ATP, resulting  a proapoptotic effect, synergically in such cases, with the one of   
Endonuclease G (Endo G) - after Hong cited by Blackman S A, 2005 [1,3] Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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15. Calcium, ROS and endogenous tissue enzymes 
(proteases, phospholipases, lipooxygenases, 
cyclooxigenases) work in concert to destroy dead or 
dying cells. 
16. Prostaglandins produce chemotactism and 
(supplementary) local/regional vasoconstriction/ 
ischemia. 
17. The oxygen breakdown of essential cell lipids 
(lipid peroxidation) and the other previously exposed 
pathways, lead, into a vicious circle, to more swelling, by 
water entering CNS - especially the brain - tissue, from 
the blood and cerebro-spinal fluids, thus leading, to more 
cell breakdown and more secondary release of toxic 
substances, that again, affect blood flow. 
18. By-products of many of these reactions, of the 
events’ cascade pathways, also stimulate the glial cells 
(first of all the astrocytes, which have a complex, vital 
role - “housekeeping” - within the NS): to emit “signaling” 
molecules, instructing to proliferate, in the attempt to 
replace/repair the destroyed/lost nevraxial tissue; this 
results mainly, in gliosis and (unfortunately) in scars (a 
major source for further limits in CNS recovery). 
Additionally to the lack of self repair significant skills 
and to the extensive secondary damages pathways, in 
the CNS, for reasons yet unclear, there are also strong 
inhibitors mainly of axonal re-growth. Hence, among the 
main  nevraxial - afore emphasized - limits in self 
recovery after injuries, there are also some inner 
obstacles that prevent CNS cells’ regeneration, 
generically called the "braking" machinery in neurons: 
tightly related to the Neurite Outgrowth Inhibiting 
(NOGO) protein and receptors (Schwab et al., since the 
middle eighties [14,15,16]) and more generally, to the rho 
family of receptors(17); this family of receptors  relays on a  
 
protein called TAJ or TROY and another one - p75 - that 
acts as an important part of the same family of receptor 
complex proteins - called TNF receptors - on neurons, 
responding to growth-inhibitory molecules in myelin and 
thus, preventing the cable-like axons’ (re)-growth of 
injured neurons in CNS: acceptance of these inhibitory 
molecules, like a key fitting a lock and switched-on, 
results in inhibitory signaling, within the neuron [18]. 
Today, more than 500 substances are or have been 
studied for neuroprotective properties. 
As traumatic and ischemic injuries in both, the brain 
and the spinal cord, entail/contain very resembling/rather 
overlapping - as mechanisms types within the patho-
physiological events’ cascade, leading to secondary 
lesions - the ”good news” is: neurotrophic and especially, 
pleiotropic substances, conceptually (and practically - 
growing evidences19) thus justify a quite large clinical 
utility spectrum.  
Cerebrolysin is a peptide mixture obtained by 
standardized enzymatic (proteo)lysis breakdown of 
purified porcine brain proteins. It consists of 
approximately 25% biologically active low molecular 
weight peptides and amino acids that are able to 
penetrate the blood - brain barrier in significant amounts 
and mimic the effects of NGF. 1 ml of injectable solution 
contains 215,2 mg of protein lysate and excipients 
(sodium hydroxide, water). The injectable solution does 
not contain proteins, lipids, or other antigenic molecules.  
As it will be seen further, it targets and counteracts 
many essential pathways of the secondary damage 
cascade and concomitantly, stimulates/ facilitates 
mechanisms of re-adapting and (limited) self repair in 
CNS injuries, i.e. the corollary - relatively rare and most 
beneficial - pleiotropic effect: 
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Fig. 2 Correspondence between Cerebrolysin’s main actions and pathways of the secondary injuries cascade it targets/ 
counteracts Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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•  Cerebrolysin inhibits both µ- and m-calpain in an 
(also) dose-dependent manner. The protease 
inhibition is non-competitive and reversible; 
•  Therefore, Cerebrolysin protects the 
cytoskeleton elements susceptible to calpain 
degradation: in neuronal cell cultures, it reduces 
the loss of (morpho-functional very important) 
Microtubule-associated protein (MAP) 2, after a 
cell injury. 
Below - some effective, intimate histopathological 
outcomes of the treatment with Cerebrolysin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Indications: As already emphasized, Cerebrolysin 
exhibits complex neuroprotective and neurotrophic - 
pleiotropic - actions. These effects have been investigated 
and confirmed in various cell culture and animal models of 
neuro-degeneration and ischemic injuries, as well as in 
clinical trials.  
            The window of opportunity in acute stroke is 
considered to be of 24 hours. 
Clinical trials have demonstrated significant motor and 
cognitive improvements in stroke and dementia patients, 
leading to consistent amendments to their quality of life 
(QOL). 
   Interactions: Cerebrolysin should not be mixed in 
perfusion with neutral amino acid solutions. The doses of 
anti-depressive medication and particularly, of 
monoamine oxidase inhibitors (MAOIs) should be lowered 
if used in conjunction with Cerebrolysin. 
   The  side effects of Cerebrolysin are infrequent and 
usually mild and transient: agitation (aggressiveness, 
insomnia, rarely hallucinations), confusion, tremor, allergic 
reactions - very rare, in our expertise (fever, skin 
reactions, pruritus, local vascular reactions, headache, 
neck pain, limb pain, lower backache, dyspnea, chills, 
shock-like state), vertigo, headache, hypertension or 
hypotension, hyperventilation, hypertonia or hypotonia, 
fatigue, depression, apathy, flu-like symptoms, gastro-
intestinal troubles (loss of appetite, dyspepsia, diarrhea, 
constipation, nausea, vomiting), rapid injection may cause 
heat sensation, sweatiness, dizziness, rarely palpitations 
or cardiac arrhythmias, injection site reactions (irritation, 
pruritus, burning sensation). 
Contraindications are: hypersensitivity to the protein 
lysate or to the excipients; epilepsy, especially grand mal 
convulsions (Cerebrolysin treatment may increase the 
frequency of seizures); severe or acute kidney failure; 
there is no available information on the safety of 
Cerebrolysin during pregnancy and lactation in humans, 
though animal studies found no toxic effects; some 
studies have shown that Cerebrolysin can be safely used 
in patients with acute hemorrhagic stroke. 
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Fig. 3 Capase inhibition by Cerebrolysin - Caspase 3 activity 
measured 48 hours after a lesion with 6µM ionomycin: 
Cerebrolysin‘s inhibition is dose-dependent (by courtesy of 
Ebewe) 
Fig. 4 Calpain inhibition by Cerebrolysin [20] : 
Fig. 5  Neural cell cultures exposed to hypoxic lesions (21)   - -   
protection by Cerebrolysin of  the Microtubule-Associated 
Protein (MAP) 2 - in vitro: A, B, C - non-lesioned controls; a, 
b, c - lesioned controls; a’, b’, c’ - lesioned, Cerebrolysin 
treated Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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Objective  
The objective of this study was to assess the 
outcomes obtained in our PR(n-m)M Clinic Division with 
Cerebrolysin, compared to patients who did not receive 
such neuroprotective / neurotophic (pleiotropic) therapy. 
Material and methods 
The study included two lots of patients, admitted 
during 2007-2009: 69 treated with Cerebrolysin (22 F, 47 
M; Average: 59.333; Mean of age: 61.0 Years old; 
Standard deviation 16.583) and respectively, 70 - controls 
(41 F, 29 M; A: 70.014; M.o.a.: 70.5 Y.o.; S.d.: 6.270). 
Study design  
A comparative analysis between Cerebrolysin (10 ml 
x 2/ day, i.v. x 3 weeks), vs. patients non-treated with 
Cerebrolysin (all the inpatients received aside, a rather 
equivalent complex, pharmacological and physical 
therapy). 
The Cerebrolysin treated lot has been constituted on 
a random base, “naturally” represented by the periods, 
within the duration of our study, when our hospital’s 
pharmacy could supply this drug. 
 
 
 
 
 
 
All cases were admitted in PR (n-m)M Clinic Division, 
mainly in early subacute stage (between 10-14 days after 
the initial injury) transferred from the neurosurgery and 
neurology departments in Bucharest and the surrounding 
areas (70,65% cases), but also from the entire country - 
our Clinic is the National Reference Centre for 
Neurorehabilitation - or readmitted, within the first year 
after injury. 
The total number of assessed items was 13, among 
which the most contributive, in relation to the score of the 
Functional Independence Measure at discharge (d FIM), 
according to our clinical rehabilitative results, were the 
first five of them: 
•  admission/ discharge Functional Independence 
Measure (aFIM)  
•  number of physical therapy days (PT/KT)  
•  number of hospitalization days (H) 
•  age (A) 
•  days until first knee functional extension (KE) 
•  days until the first walk between parallel bars 
(WPB) 
•  days until the first independent walk recovery 
(IWR)  
•  days until the first cane assisted walk recovery 
(CWR) 
•  days until the first stairs ascent /descend 
recovery (SR) 
•  etiology (E) 
•  gender (G)  
•  evolutive status at discharge (ES) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mathematical methodology 
Our statistical analysis used, as desired, a 
differentiation method to assess the validity of outcomes, 
the T TEST; previously this entailed the mathematical 
evaluation of the two studied populations’ normality of 
distribution. Hence, if a population is normally distributed - 
according to the frequency histogram and the following 
calculation tools: Min, Max, Aver., St. Dev. - it is to be 
expected strong validity results of the applied T TEST; if 
the population is not normally distributed - as it was, 
mostly the case of the assessed parameters within our 
study - we applied the CHI SQUARE TEST, by the 
frequency histogram - giving thus, potential for evaluation 
to more of our assessed parameters. 
There have been done also correlation analysis, to 
objectify the statistical assessed variables/ phenomena’ 
dependence, between them, quantified by the calculated 
Fig. 6 The distribution of the two studied lots, by etiology
Fig. 7 The (worldwide accepted as standardized assessment 
tool) Functional Independence Measure (FIM) Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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value - through the EPI INFO soft - of the correlation 
coefficients (positive or negative). Hence, once 
emphasized a certain dependence between variables, 
they had to be quantified by regression assays; as it is 
well known, there are simple regressions (with the generic 
formula: Y = a+bX, where: Y = the dependent variable; X 
= the independent variable; a and b = regression 
coefficients; b is also the straight line’s slope, 
representing the amount in which Y’s value changes 
when X’s value varies by one unit) and multiple ones: 
applied to this study, all the independent variables (a FIM, 
PT/KT, H, A, KE, WPB, SR, EXR, CWR, IWR, G, E) are 
simultaneously intervening. Thus, we were interested in 
the construction of a mathematical model/ equation, in 
which the dependent variable Y is d FIM and the 
independent variables are: X1 (a FIM), X2 (PT/KT) , etc. 
The resulting formula was: Y = B0 + B1 X1 + B2 X2 + … + 
Bn X n - multiple regression - where:Y = the dependent 
variable (d FIM), B0 = the tabular appropriate correlation/ 
regression coefficient, B1  = the correlation/ regression 
coefficient of a FIM, etc.  
 
 
 
 
 
 
 
 
 
 
 
 
Results and discussions 
       First, two studied populations’ normality distribution 
level has been assessed, with respect to each main 
parameter, starting with the first - focused (but) non 
functional/ analytical - one, PT/KT: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  PT/KT Cerebro 
Average  18.92753623 
St. dev.  10.96695416 
  PT/KT witness 
Average  16.6 
St. dev.  12.50437605 
   
p value  0.122600944 
 
 
freq. 
PT/KT
cer.
freq. 
PT/KT 
witn.     
normal 
cer. 
normal 
witn. 
8,5 
0,058
0  0,2286 4  16 
0,18518
4 
0,20692
9 
16,5 
0,463
8  0,3143 32  22 
0,28397
1 
0,25522
6 
24,5 
0,275
4  0,2714 19  19 
0,25577
1 
0,20905
7 
32,5 
0,043
5  0,1286 3  9  0,13531
0,11372
2 
40,5 
0,115
9  0,0429 8  3 
0,04204
5 
0,04108
3 
48,5 
0,014
5  0,0000 1  0 
0,00767
4 
0,00985
6 
56,5 
0,014
5  0,0000 1  0 
0,00082
3  0,00157
64,5 
0,014
5  0,0000 1  0  5,18E-05
0,00016
6 
72,5 
0,000
0  0,0000 0  0  1,92E-061,17E-05
80,5 
0,000
0  0,0000 0  0  4,16E-085,45E-07
88,5 
0,000
0  0,0143 0  1  5,31E-101,69E-08
 
1,000
0  1,0000 69  70 
0,91083
2 
0,83762
1 
 
As (also) emphasized by the histogram below, a 
statistically significant populations’ normality distribution 
hasn’t been observed: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Accordingly, we proceeded to CHI2 TEST assay; the 
resulted p=0.152824, emphasizes that statistical 
A+bx
B  + B X  +B X +.... o 11 22
Fig. 8 The curves for simple and respectively, for multiple 
regression 
Fig. 9 Frequency  distribution 
 
Table 1. Normality 
distribution values of 
the two assessed 
populations, regarding 
PT/KT parameter 
 
Fig. 10 Histogram emphasizing the level of the two studied 
populations’ normality distribution, regarding PT/KT Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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significant differences between the two lots, regarding this 
parameter have not been objectified: 
 
 
 
 
PT/KT  Cerebolysin  Witness 
<10  9  15 
10-17  29  30 
18-26  17  16 
>26  14  9 
chi2 test val. p  0.152824   
0.5 val. p  0.076412   
 
Similarly, related to the frequency distribution, we 
comparatively analyzed the two populations’ normality, 
regarding the - focused (but) non functional/ analytical - H 
parameter:   
 
   H  Cerebrolysin 
Average  26.17391304 
St. dev.  15.27970253 
   H witness 
Average  22.98571429 
 St. dev.  17.41354866 
    
p value   0.126540558 
 
   freq. H cer. freq. H witn.      normal cer. normal witn.
6,5  0,0145  0,1286  1 9  0,136765  0,175623 
18,5  0,3333  0,2714  23 19  0,276188  0,265947 
30,5  0,3768  0,3714  26 26  0,301002  0,250478 
42,5  0,1159  0,1286  8 9  0,177039  0,146725 
54,5  0,1159  0,0571  8 4  0,056196  0,053456 
66,5  0,0145  0,0286  1 2  0,009627  0,012113 
78,5  0,0145  0,0000  1 0  0,00089  0,001707 
90,5  0,0145  0,0000  1 0  4,44E-05  0,00015 
102,5  0,0000  0,0000  0 0  1,2E-06  8,16E-06 
114,5  0,0000  0,0000  0 0  1,74E-08  2,77E-07 
126,5  0,0000  0,0143  0 1  1,36E-10  5,83E-09 
  1,0000  1,0000  69 70  0,957752  0,906207 
 
As (also) emphasized by the histogram below, a 
statistically significant normality distribution hasn’t been 
observed: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Therefore, we proceeded to CHI2 TEST assay. It 
resulted p=0,013259, i.e. there has been objectified 
statistical significant difference, but at limit, between the 
two lots, regarding H, in ”favor” of the Cerebrolysin lot. 
 
 
 
 
H  Cerebrolysin  Witness 
<11  4  15 
11-30  46  39 
31-50  14  13 
>50  5  3 
chi2 test   
val. p  0.013259   
0.5 val. p  0.006629   
 
The interpretation of this discriminative result should 
be done within a wider, more complex context, i.e. the 
mean duration of H is, from economical objective reasons, 
limited, thus having - obviously - including administrative 
constrains in our clinic activity. Hence, one of the main 
normal medical criterion to discharge a patient is when 
he/she reaches a plateau in the actual stage of the 
rehabilitative process (usually of long term). Therefore, a 
larger number of H, means the respective patient had a 
prolonged/ sustained, favorable evolution.  
The two studied populations’ normality distribution 
has also been assessed, regarding the d FIM composed/ 
exhaustive parameter: 
 
 
 
 
 
 
freq. d FIM 
cer. 
freq. d   FIM 
witn.     
normal 
cer. 
normal 
witn. 
6,5  0,0580  0,0000  4  0  0,013924 0,001594
18,5 0,0000  0,0000  0  0  0,03237  0,009536
30,5 0,0145  0,0143  1  1  0,063202 0,038648
42,5 0,0725  0,0857  5  6  0,103636 0,106099
54,5 0,0435  0,1286  3  9  0,142719 0,197308
66,5 0,2609  0,2571  18  18 0,165064 0,248557
78,5 0,1884  0,3000  13  21 0,160332 0,212108
90,5 0,1159  0,1143  8  8  0,130792 0,122613
102,5 0,1304  0,0571  9  4  0,089606 0,048014
114,5 0,0290  0,0000  2  0  0,051558 0,012736
126,5 0,0725  0,0429  5  3  0,024914 0,002289
        1,0000  1,0000  68  70 0,978117 0,999502
            
As emphasized by the histogram below, a 
statistically significant normality of distribution has 
been observed: 
Table 2 The tabular form of the CHI2 TEST results regarding 
PT/KT 
 
 
Table 3 Normality 
distribution values of the two 
assessed populations, 
regarding H parameter 
 
Fig. 11 Histogram emphasizing the level of the two studied 
populations’ normality distribution, regarding H 
Table 4 The tabular form of the CHI2 TEST results regarding H 
Table 5 Normality distribution values of the two assessed 
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Accordingly, we could use the T TEST; the results 
below, statistically significant emphasized the lack of 
difference between (regarding both, the independent and 
the dependent, related variables) the global/ synthetic 
outcomes, in the two lots – a FIM (p=0.3682) and d FIM 
(p=0.2453): 
 
 
 
 
T TEST  a FIM  d FIM 
Average  53.36231884  70.5 
St. dev.  24.37149433   28.72281 
Average  54.52857143   67.61429 
St. dev.  15.31005299   19.22807 
p value  0.368264131   0.245307 
 
Regarding the comparative assessment of the key 
focused on neuro-motor rehabilitative outcomes, 
functional/ analytical parameter, KE, related to the 
frequency distribution, there hasn’t been observed a 
statistically significant populations’ normality distribution: 
 
  KE 
Average  10,53623 
St. dev  9,671942 
   
Average  11,24286 
St. dev  10,46379 
   
p value  0,339934 
 
  freq KE cer 
freq KE 
witn      normal cer  normal witn 
2,5  0,3043  0,4000  21  28  0,087621  0,080677 
5,5  0,0435  0,0000  3  0  0,108054  0,098386 
8,5  0,0870  0,0429  6  3  0,12103  0,110515 
11,5  0,0870  0,0714  6  5  0,123129  0,114343 
14,5  0,2174  0,0571  15  4  0,113775  0,108969 
17,5  0,0290  0,0429  2  3  0,095488  0,095652 
20,5  0,1159  0,1714  8  12  0,07279  0,077337 
23,5  0,0435  0,0429  3  3  0,050397  0,057595 
26,5  0,0290  0,1143  2  8  0,031693  0,039508 
29,5  0,0145  0,0286  1  2  0,018102  0,024962 
52,5  0,0290  0,0286  2  2  1,01E-05  4,81E-05 
  1,0000  1,0000  69  70  0,822089  0,807992 
Consequently, we proceeded to CHI2 TEST assay. It 
resulted a statistically significant difference in favor of the 
Cerebrolysin treated lot, i.e. the number of days until the 
first achievement of a functional knee extension in the 
paretic limb, was significantly shorter in the study lot 
(p=0,000733): 
 
 
 
KE  Cerebrolysin  Witness 
 <3  21  28 
3-12  18  9 
13-22  25  20 
 >23  5  13 
chi2  test val. p   0,000733   
0.5 val p  0,000366   
 
The same lack of statistically significant populations’ 
normality distribution and consequently, similar 
mathematical methodology and results, were used/ 
obtained for another key focused on neuro-motor 
rehabilitative outcomes, functional/ analytical parameter - 
WPB (p=0,000000): 
 
  WPB 
Average  6,942029 
St. dev.  9,73152 
   
Average  8,871429 
St. dev.  11,61823 
   
p value  0,145084 
 
 
freq. 
WPB 
cerebr. 
freq. WPB 
witn.     
normal 
cerebrol.  normal witn.
2,5  0,5652  0,5857  39  41  0,087621  0,080677 
5,5  0,0290  0,0000  2  0  0,108054  0,098386 
8,5  0,0580  0,0000  4  0  0,12103  0,110515 
11,5  0,0580  0,0429  4  3  0,123129  0,114343 
14,5  0,0580  0,0286  4  2  0,113775  0,108969 
17,5  0,0870  0,0571  6  4  0,095488  0,095652 
20,5  0,0725  0,0857  5  6  0,07279  0,077337 
23,5  0,0000  0,0286  0  2  0,050397  0,057595 
26,5  0,0000  0,1000  0  7  0,031693  0,039508 
29,5  0,0000  0,0143  0  1  0,018102  0,024962 
52,5  0,0725  0,0571  5  4  1,01E-05  4,81E-05 
  1,0000  1,0000  69  70  0,822089  0,807992 
 
 
 
 
WPB  Cerebrolysin  Witness 
<3  39  41 
3-12  11  3 
13-22  14  13 
>23  5  13 
val. of  p 
chi2 test  7,75E-06   
0.5 val. of p  3,87E-06   
Fig. 12 Histogram emphasizing the level of the two studied 
populations’ normality distribution, regarding d FIM 
Table 6 The tabular form of the T TEST results, regarding a 
FIM and d FIM 
 
 
Table 7 Normality distribution 
values of the two assessed 
populations, regarding KE 
parameter  
 
Table 8 The tabular form of the CHI2 TEST results, regarding KE 
 
 
Table 9 Normality distribution 
values of the two assessed 
populations, regarding WPB 
parameter 
 
Table 10 The tabular form of the CHI2  TEST results, 
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For the other focused on neuro-motor rehabilitative 
outcomes, functional/analytical parameters, the number of 
patients suitable to be introduced in histograms, was not 
enough for concluding results; therefore, we consider the 
total number of the studied patients within both lots, to be 
rather small. 
Regarding correlation tests in our study, multiple 
regression analysis mainly evaluated predictor 
contributivity matters: Hence, the way – of contributivity/ 
reliability measure - the two analyzed populations 
aggregate, for (all parameters considered) each studied 
individual, to the - resulting/ proposed by the EPI INFO 
soft - optimal appropriate multiple regression formula, 
regarding the whole predictability level of our study is 
emphasized in the graphic below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Multiple regression assessment also emphasized the 
dependent variable d FIM was tightly correlated with the 
independent variable a FIM (r=0.8660, p=0.0000) in the 
whole studied population; the significant statistic 
correlation between d FIM and a FIM (p=0.0000), with its 
calculated coefficient (r=0.8660), objectifies, at the same 
time, the importance of the initial correct/ complete clinical 
and functional evaluation, including its consistent 
contributivity as a predictor of a complex therapeutic/ 
rehabilitative (appropriate) management’s  efficacy. 
 
 Additionally, close to the statistical significance limit, 
the - focused (but) non functional/ analytical - parameters: 
PT/KT (r=5.8520, p=0.0115) and H (r=- 4.0070, p=0.0159) 
were placed, by their predictor contributivity: 
 
 
 
 
 
  r  p 
a FIM  0.8660  0.000000 
PT/KT  5.8520  0.011572 
H  -4.0070  0.015943 
Constant  23.7960 0.005513 
Determ. R2  0.5400   
 
For the other parameters (again) the number of 
patients in which these could be assessed, was not large 
enough for statistical contributivity, according to the 
multiple regression design/ requirements, within these 
dimensions of the studied lots.  
On the other hand, the statistical significance of the 
discriminative tests’ results that support the hastening, in 
reaching neurorehabilitative, analytical, outcomes - afore 
emphasized - effect of Cerebrolysin, represents an - 
including mathematically based on - strong, objective 
reason to continue enlarging our studied groups. 
Conclusions 
       Cerebrolysin  administration  proved  to  statistically 
significant improve the speed of achieving of, at least two 
key, focused on neuro-motor rehabilitative outcomes, 
functional/ analytical parameters: KE and WPB; actually, 
this goes with both, common sense (but mainly based on 
clinical evidence/expertise) and scientific information: 
modern pleiotropic drugs – Cerebrolysin is emblematic – 
obviously cannot cure the CNS lesions (not even provide 
complete restitution to lost functions)  but they can 
instead, really hasten recovery.  
       
Moreover, considering the objectified, imperious necessity 
to substantially enlarge the studied lots, of our study, we 
have now initiated a comprehensive, national, 5 year, 
retrospective, multi-centre (based on unitary data 
acquisition - see below - frame and mathematical 
apparatus) study, to evaluate the results of the treatment 
with Cerebrolysin in traumatic brain injuries (TBI). 
 
 
 
 
1  2  3  4  5  6  7  8  9  10  11  12 
Treatment 
No.  Gend.  Age 
(y.o.)  Etio.  Days  
of hos.  GCS 
M 
(best 
mot. 
res.) 
O (eye 
resp.) 
V 
(best 
verb. 
res.) 
(spec.) 
Simpt.  CT  Surg..  Cons. 
Fig. 13 The curve for multiple regression, plotted based on 
the dependent-independent variables, correlation calculated 
accounts (mathematical analysis with EPI INFO soft) within 
our two studied lots 
Table 11 The multiple regression analysis results, regarding 
the two main - focused (but) non functional/ analytical - 
parameters: PT/KT and H 
Fig. 14 The ”standardized”, 15 columns table, to summarize, within an unitary data base,  each patient evaluated within the 5 
years retrospective, multi-centre, study (by Ebewe coutesy) Journal of Medicine and Life Vol. 2, No.4, October-December 2009 
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13  14  15 
Cerebrolysin prescribed during hospitalization  Cerebrolysin prescribed at 
discharge 
Moment of introduction  Period (days)  Quantity 
Glasgow 
Outcome 
Score (GOS) at 
discharge  Period (days)  Quantity 
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